Radioligand Therapy Market is Accelerated by Targeted Cancer Treatments and Growing FDA Approvals | Novartis AG, Bayer AG., Eli Lilly and Company., Sanofi, among others

Radioligand Therapy Market reached US$ 2.41 billion in 2024 and is expected to reach US$ 15.80 billion by 2033, growing at a CAGR of 21.9% during the forecast period 2025-2033.

The latest Radioligand Therapy Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/radioligand-therapy-market?ophp

Radioligand therapy delivers targeted radiation to cancer cells via radioactive molecules bound to tumor-specific ligands. This market is gaining traction in prostate, neuroendocrine, and thyroid cancers, driven by rising demand for precision oncology, promising clinical outcomes, and increased investment in radiopharmaceutical innovation.

Radioligand Therapy Market Competitors Overview:

Radioligand Therapy Market Major Players:

The major players in the radioligand therapy market are Novartis AG and Bayer AG.

Radioligand Therapy Market Emerging Players:

The emerging players in the radioligand therapy market are Eli Lilly and Company., Lantheus, Curium, AstraZeneca, ITM Isotope Technologies Munich SE, Telix Pharmaceuticals Limited, Oranomed, Sanofi, RadioMedix, Inc., Clarity Pharmaceuticals, Ariceum Therapeutics, and Blue Earth Therapeutics, among others.

Important Industry Updates of 2024 and 2025:

✅ In May 2025, Blue Earth Therapeutics announced the enrollment of the first two patients in a Phase 2 clinical trial for its radio hybrid, lutetium-labelled, PSMA-targeted investigational radioligand therapy. The primary measure of efficacy will be the proportion of patients achieving a ≥50% reduction in PSA levels, as well as assessing radiographic progression-free survival and patient safety.

✅ In March 2025, Novartis AG announced that the U.S. Food and Drug Administration (FDA) approved the extended application of Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer. With this approval, the target patient population of Pluvicto is expected to triple.

Radioligand Therapy Market Segments Overview:

∎ By Type (Lutetium Lu-177, Radium Ra 223 Dichloride, Others)
∎ By Target (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR))
∎ By Application (Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs), Others)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/radioligand-therapy-market?ophp

Methodology and Scope:

This Radioligand Therapy Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.

Regional Overview for Radioligand Therapy Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=radioligand-therapy-market?ophp

The Report Includes:

➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.

People Also Ask:

➤ What are the global sales, production, import, and export trends in the Radioligand Therapy market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the Radioligand Therapy market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.